Ocílio Ribeiro Gonçalves, Arquimedes Barros Nascimento, Victor Gonçalves Soares, David Abraham, Gabriel de Almeida Monteiro, João Luís Reis Freitas, Jonatas Paulino da Cunha Monteiro Ribeiro, Bianca Leal Ribeiro, João Victor Araújo de Oliveira, Marco Antonnio Rocha Dos Santos, João Paulo Mota Telles, Flávio Sekeff-Sallem, Kelson James Almeida
{"title":"Statins as potential disease-modifying therapy of Parkinson's disease: a systematic review and meta-analysis with trial sequential analysis.","authors":"Ocílio Ribeiro Gonçalves, Arquimedes Barros Nascimento, Victor Gonçalves Soares, David Abraham, Gabriel de Almeida Monteiro, João Luís Reis Freitas, Jonatas Paulino da Cunha Monteiro Ribeiro, Bianca Leal Ribeiro, João Victor Araújo de Oliveira, Marco Antonnio Rocha Dos Santos, João Paulo Mota Telles, Flávio Sekeff-Sallem, Kelson James Almeida","doi":"10.1007/s13760-024-02709-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Recent evidence indicates that statins have anti-inflammatory and antioxidant effects, leading to several investigations of whether statins have a neuroprotective effect and may benefit patients with Parkinson's disease (PD). However, the potential mechanisms of this class of medications as modifiers of the course of PD in already diagnosed patients is still unclear.</p><p><strong>Objectives: </strong>To assess the effectiveness of statins as modifiers of established PD.</p><p><strong>Methods: </strong>Two investigators systematically searched for randomized clinical trials and observational studies comparing PD patients treated with statins versus those treated without statins. The search was conducted in PubMed, Embase, Cochrane, and Web of Science. The outcome of interest was the change in the MDS-UPDRS III (Movement Disorder society-Unified Parkinson's Disease Rating Scale Part III) and UPDRS III scores from baseline. Statistical analysis was performed using R Studio 4.3.2.</p><p><strong>Results: </strong>Four studies, totaling 472 patients, were included. The standardized mean difference for the MDS-UPDRS Part III and UPDRS Part III scales between statin and non-statin groups was - 0.13 (95% CI - 0.44 to 0.17; p = 0.39; I<sup>2</sup> = 58%), and there was no statistical significant difference regarding this outcome.</p><p><strong>Conclusion: </strong>There was no statistical significance for the potential clinical benefit of statins as modifiers of the disease course in PD patients.</p>","PeriodicalId":7042,"journal":{"name":"Acta neurologica Belgica","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta neurologica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13760-024-02709-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Recent evidence indicates that statins have anti-inflammatory and antioxidant effects, leading to several investigations of whether statins have a neuroprotective effect and may benefit patients with Parkinson's disease (PD). However, the potential mechanisms of this class of medications as modifiers of the course of PD in already diagnosed patients is still unclear.
Objectives: To assess the effectiveness of statins as modifiers of established PD.
Methods: Two investigators systematically searched for randomized clinical trials and observational studies comparing PD patients treated with statins versus those treated without statins. The search was conducted in PubMed, Embase, Cochrane, and Web of Science. The outcome of interest was the change in the MDS-UPDRS III (Movement Disorder society-Unified Parkinson's Disease Rating Scale Part III) and UPDRS III scores from baseline. Statistical analysis was performed using R Studio 4.3.2.
Results: Four studies, totaling 472 patients, were included. The standardized mean difference for the MDS-UPDRS Part III and UPDRS Part III scales between statin and non-statin groups was - 0.13 (95% CI - 0.44 to 0.17; p = 0.39; I2 = 58%), and there was no statistical significant difference regarding this outcome.
Conclusion: There was no statistical significance for the potential clinical benefit of statins as modifiers of the disease course in PD patients.
期刊介绍：
Peer-reviewed and published quarterly, Acta Neurologica Belgicapresents original articles in the clinical and basic neurosciences, and also reports the proceedings and the abstracts of the scientific meetings of the different partner societies. The contents include commentaries, editorials, review articles, case reports, neuro-images of interest, book reviews and letters to the editor.
Acta Neurologica Belgica is the official journal of the following national societies:
Belgian Neurological Society
Belgian Society for Neuroscience
Belgian Society of Clinical Neurophysiology
Belgian Pediatric Neurology Society
Belgian Study Group of Multiple Sclerosis
Belgian Stroke Council
Belgian Headache Society
Belgian Study Group of Neuropathology
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
